Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer [Breast Cancer]
Conclusion
We did not find racial disparities in ODX testing for node-negative patients for whom ODX testing is guideline recommended and widely covered by insurers. However, our findings suggest that a newer, non–guideline-concordant application of ODX testing for node-positive breast cancer was accessed less by black women than by non-black women, reflecting more guideline concordant care among black women.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Roberts, Weinberger, Dusetzina, Dinan, Reeder-Hayes, Carey, Troester, Wheeler Tags: Chemotherapy, Quality of Care Breast Cancer Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Genetics | HIV AIDS | Insurers | Pathology | Study | Women